| A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells A Ray, D Ravillah, DS Das, Y Song, E Nordström, J Gullbo, ... British journal of haematology 174 (3), 397-409, 2016 | 59 | 2016 |
| Systems biology analyses show hyperactivation of transforming growth factor-β and JNK signaling pathways in esophageal cancer AE Blum, S Venkitachalam, D Ravillah, AK Chelluboyina, ... Gastroenterology 156 (6), 1761-1774, 2019 | 49 | 2019 |
| Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis D Ravillah, A Mohammed, L Qian, M Brewer, Y Zhang, L Biddick, ... Journal of Pharmacology and Experimental Therapeutics 348 (1), 59-68, 2014 | 17 | 2014 |
| The Ephrin B2 receptor tyrosine kinase is a regulator of proto-oncogene MYC and molecular programs central to barrett’s Neoplasia S Venkitachalam, D Babu, D Ravillah, RM Katabathula, P Joseph, ... Gastroenterology 163 (5), 1228-1241, 2022 | 11 | 2022 |
| Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats NB Janakiram, A Mohammed, D Ravillah, CI Choi, Y Zhang, D Desai, ... Oncology reports 30 (2), 952-960, 2013 | 11 | 2013 |
| Anti-myeloma activity of a novel free radical inducer RRx-001 DS Das, Z Tian, A Ray, D Ravillah, Y Song, PG Richardson, B Oronsky, ... Blood 124 (21), 4712, 2014 | 8 | 2014 |
| Anti-myeloma activity of a novel glutaminase inhibitor CB-839 DS Das, D Ravillah, A Ray, Y Song, NC Munshi, PG Richardson, ... Blood 124 (21), 3439, 2014 | 8 | 2014 |
| HNF4A defines molecular subtypes and vulnerability to Transforming growth factor β-pathway targeted therapies in cancers of the distal esophagus AE Blum, D Ravillah, S Singh, Y Miao, AM Kresak, JE Willis, MI Canto, ... Gastroenterology 163 (5), 1457-1460, 2022 | 3 | 2022 |
| Genome-scale analysis identifies novel transcript-variants in esophageal adenocarcinoma BPD Purkayastha, ER Chan, D Ravillah, L Ravi, R Gupta, MI Canto, ... Cellular and Molecular Gastroenterology and Hepatology 10 (3), 652-654. e17, 2020 | 3 | 2020 |
| Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib and IMiD® Immunomodulatory Drug Pomalidomide DS Das, D Ravillah, A Ray, Y Song, PG Richardson, M Trikha, ... Blood 124 (21), 2099, 2014 | 2 | 2014 |
| Abstract A35: Chemoprevention of colon carcinogenesis in F344 rats by Se,Se′‐1,4‐phenylenebis(1,2‐ethanediyl)bis‐isoselenourea (PBISe) a novel analog of … NB Janakiram, A Mohammed, D Ravillah, CI Choi, Y Zhang, D Desai, ... Cancer Prevention Research 3 (1_Supplement), A35-A35, 2010 | 2 | 2010 |
| Discovery and Initial Characterization of Long Intergenic Noncoding RNAs Associated With Esophageal Adenocarcinoma D Ravillah, AML Kieber-Emmons, S Singh, A Chak, DG Beer, ... Gastroenterology 165 (2), 505-508. e7, 2023 | 1 | 2023 |
| Targeting proteasome ubiquitin receptor RPN13/ADRM1 in multiple myeloma Y Song, DS Das, A Ray, D Ravillah, NC Munshi, D Chauhan, ... Blood 124 (21), 419, 2014 | 1 | 2014 |
| 930 MUTATIONS IN XANTHENE DEHYDROGENASE (XDH) ASSOCIATED WITH INHERITED SUSCEPTIBILITY TO BARRETT'S NEOPLASIA D Ravillah, BPD Purkayastha, A Blum, B Udhayakumar, S Singh, ... Gastroenterology 164 (6), S-198, 2023 | | 2023 |
| The EphB2-MYC Axis is a Major Determinant of Barrett’s Pathobiology and a Therapeutic Vulnerability in Esophageal Cancer S Venkitachalam, D Babu, D Ravillah, RM Katabathula, P Joseph, ... bioRxiv, 2021.05. 13.444044, 2021 | | 2021 |
| Su1062–Molecular Dependencies in Esophageal Adenocarcinoma: A Systems Biology Approach S Venkitachalam, A Blum, D Ravillah, AK Chelluboyina, ... Gastroenterology 156 (6), S-498-S-499, 2019 | | 2019 |
| 284–Transgenic Mouse Model Based on Vsig10L, the First Susceptibility Gene for Familial Barrett's Esophagus D Ravillah, A Baskin, NA Berger, RA Conlon, J Willis, SD Markowitz, ... Gastroenterology 156 (6), S-57-S-58, 2019 | | 2019 |
| SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents … A Ray, DS Das, D Ravillah, Y Song, V Macri, C Brooks, E Rowinsky, ... Blood 124 (21), 3441, 2014 | | 2014 |
| A Novel Alkylating Agent Melphalan Flufenamide Ethyl Ester Induces an Irreversible DNA Damage in Multiple Myeloma Cells A Ray, D Ravillah, DS Das, Y Song, E Nordström, J Lindberg, ... Blood 124 (21), 2086, 2014 | | 2014 |
| Targeting HADC-2: Chemopreventive effect of OSU-HDAC42 on rat colon carcinogenesis and APCmin/+ Mice intestinal tumorigenesis. D Ravillah, L Qian, M Brewer, Y Zhang, L Biddick, V Madka, JMR Patlolla, ... Cancer Research 73 (8_Supplement), 4392-4392, 2013 | | 2013 |
